In a study examining the use of magic mushrooms in Canada, nearly 80% of the respondents stated their opinion that psilocybin should be medically accessible for distressed patients. Moreover, about two-thirds of the Canadian participants from the same study concurred that psilocybin should be legally available for those requiring it.
Besides advocating for its easy availability, a substantial 84.8 percent of participants expressed that the expenses of such treatments should be borne by the public health system. A majority of Canadians view psilocybin as a credible alternative, especially for managing end-of-life distress.
[toc]
Key Findings:
- Residents of Québec, Ontario, Alberta, and British Columbia acknowledge psilocybin as a legitimate medical solution for managing end-of-life existential distress.
- Magic mushrooms are deemed safe for addressing existential distress.
- Participants in two double-blind trials experienced immediate and long-lasting benefits, with effects persisting for six months or more.
Understanding Existential Distress
Existential distress, similar to existential suffering, spiritual distress, and demoralization, arises when individuals face their mortality. This distress can lead to feelings of helplessness, isolation, anxiety, and a loss of sense of purpose and meaning. It significantly impacts patients with life-threatening conditions, potentially leading to suicidal thoughts or a wish to hasten death.
Typically, this type of distress is experienced by individuals grappling with life-threatening diseases or significant life changes. It significantly influences their mental health and overall life quality.
Existential therapy aims to address issues like anxiety, depression, grief, loneliness, apathy, despair, confusion about identity, feelings of purposelessness, and existential fear. This therapy can necessitate multiple sessions and may not be effective for everyone.
The uncertainty about the effectiveness of such therapy often leads many individuals to seek alternative treatments.
Health Canada’s Perspective on Psilocybin as a Therapeutic Option
In the past two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances in addressing complex mental disorders. Specifically, psilocybin has demonstrated a rapid and sustained reduction of existential distress in patients at the end of their lives.
Recognizing the possible efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada modified the Special Access Program in 2022. This modification permits healthcare providers to request controlled substances for their patients.
Canadian Advocacy for Psilocybin Access
A paper in the Palliative Care Journal examines societal views on psilocybin-assisted therapy for end-of-life care. The data from the study includes:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previously consumed psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% think psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys conducted in Canada, England, and Australia. The researchers note that their study is unique because it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Why Canadians Support Psilocybin Use
An increasing number of Canadians are endorsing the use of psilocybin for treatment, largely influenced by evidence from esteemed research bodies. Another factor is the perceived safety of psilocybin mushrooms for easing existential distress. Participants in various studies have not reported serious adverse health effects, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and prolonged |
| The benefits of the therapy can last up to six months or even longer. The effectiveness of the therapy is largely credited to the mystical experiences it induces, characterized by a profound sense of unity and deep emotional revelations. | ||
| The New York University Trial | A group of 29 patients were randomly chosen to be administered either psilocybin or the active placebo, niacin. | The results of this trial were closely aligned with those of the Johns Hopkins study. Participants who received psilocybin reported psychological relief and gained a renewed perspective on life and death. |
| BMC Palliative Care | Nineteen participants, including 7 doctors, 4 active nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The purpose of this study was to gather insights on how palliative care professionals perceive existential distress and their views on psychedelic therapy as a treatment option. | As per the palliative care practitioners interviewed, psychedelic-assisted therapy (PAT) appears to have potential in alleviating existential distress. |
Patient Experiences
Scientific research isn’t the only form of evidence supporting the efficacy of psilocybin. There are numerous accounts from patients that highlight its potential to enhance mental health and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her transformative experience during her assisted therapy. She visualizes herself on a raft, surrounded by nature and accompanied by imaginative creatures. This vision ingrains in her a profound realization of the universe’s interconnectedness and support, providing her with immense peace and affirmation.
Despite availing traditional mental health support, Yokoi continued to grapple with severe anxiety and distress following her diagnosis. Psilocybin therapy enabled her to re-establish a connection with her body and provided a tangible sense of love and support. This has significantly improved her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer that had metastasized to her lungs. At the time of the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy reported significant decreases in her anxiety, depression, fear of death, feelings of hopelessness, and demoralization. When asked about any shifts in her religious or spiritual beliefs since her therapy session, she stated that the experiences gave her beliefs an enhanced sense of meaning and reality.
Brenda’s Journey
During therapeutic sessions, Brenda reported experiencing death twice, which led her to no longer fear death and view it as a natural part of life. She accredited the study for initiating her healing journey from past trauma. Her data supported this profound transformation.
There was a notable decrease in anxiety and fear of death, along with an increase in spirituality.
Availability of Psilocybin Products in Canada
Psilocybin capsules and other related products designed to manage existential distress or other mental health conditions may not be readily available. However, reliable online dispensaries can be a resourceful way to acquire these products when necessary.
| Feature | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some surrounding South American countries. | Located in Cambodia, particularly around the Angkor Wat Temple. | Associated with Penis Envy mushrooms that gained popularity in the 1970s. |
| Potency | Moderately potent; recommended for beginners. | Moderate potency; suitable for novices. | Highly potent; advisable for individuals with intermediate to advanced experience. |
| Effects | Triggers a mental buzz, mild disorientation, heightened color perception, euphoria, spiritual experiences, increased creativity, and enhanced focus. | Induces an uplifting and long-lasting high, slight visual changes, enhanced creativity, euphoria, a gentle physical high, fractal images, and feelings of joy. | Facilitates deep spiritual experiences, vision quests, intense mystical experiences, increased creativity, focus, social awareness, and mood elevation. |
Ease End-of-life Discomfort with Psilocybin Products
Existential angst or end-of-life distress can heavily burden patients nearing the end of their lives. Traditional treatments may sometimes be inadequate, prompting an increase in the Canadian demand for easier access to psilocybin mushrooms in public healthcare. This growing public interest could We advocate for regulatory authorities to recognize magic mushrooms as a substantial treatment option. Acquire your psychedelics and shroom delivery from Powerful Magic Mushrooms Canada.
Frequently Asked Questions
What should patients expect during Psilocybin-Assisted Therapy?
Experiences with Psychedelic-assisted therapy (PAT) can differ greatly among patients, and meticulous preparation and compliance with certain guidelines are crucial for a positive result. It’s essential for patients to go through extensive screening and mental readiness before taking the substance.
- Prior to the Session: Patients undergo an all-inclusive evaluation. The therapist reviews the patient’s goals and expectations to set intentions for the session. The therapist then outlines the potential effects of the process and what the patient can foresee during the session.
- During the Session: A controlled dose of the substance is given to the patients in a serene, distraction-free environment to foster relaxation and self-reflection. The therapist provides ongoing support and direction throughout.
- After the Session – Integration Therapy: This therapy assists the patient in interpreting and assimilating their experiences. Follow-up sessions provide continuous support and counselling to reinforce the insights and changes achieved during therapy.
How does psilocybin affect distressed patients’ brains?
Psilocybin interacts with the brain by binding to serotonin receptors, particularly the 5-HT2A receptor. This interaction can induce alterations in perception, mood, and cognition, culminating in substantial shifts in consciousness, emotional breakthroughs, and new viewpoints.
Is psilocybin therapy available to all?
Psilocybin therapy isn’t appropriate for everyone. Patients with certain mental health conditions or existential distress are carefully screened to eliminate those with a history of psychosis.
Related Content:
